<DOC>
	<DOCNO>NCT02969317</DOCNO>
	<brief_summary>The primary objective study ass pharmacokinetics olodaterol monotherapy ( 5 μg ) tiotropium + olodaterol Fixed Dose Combination ( FDC ) ( 5 μg/ 5 μg ) deliver RESPIMAT inhaler single dose steady state Chinese patient Chronic Obstructive Pulmonary Disease ( COPD ) . The secondary objective ass safety olodaterol monotherapy ( 5 μg ) tiotropium +olodaterol FDC ( 5 μg/ 5 μg ) deliver RESPIMAT inhaler 3 week daily treatment Chinese patient COPD .</brief_summary>
	<brief_title>Bioavailability Tiotropium + Olodaterol Fixed-dose Combination ( 5 μg/ 5 μg ) Olodaterol 5μg Chinese COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : All patient must sign informed consent consistent International Conference HarmonisationGood Clinical Practice ( ICHGCP ) guideline local legislation prior studyrelated procedure , include medication washout restriction . All patient must diagnosis Chronic Obstructive Pulmonary Disease ( COPD ) must meet follow spirometric criterion : Patients must relatively stable airway obstruction postbronchodilator Forced Expiratory Volume one second ( FEV1 ) &gt; =30 % predict normal &lt; 80 % predict normal ( ECSC , ; postbronchodilator FEV1/ Forced Vital Capacity ( FVC ) &lt; 70 % Visit 1 Male female patient , 40 year age old . Patients must current exsmokers smoke history 10 pack year . Patients never smoke cigarette must exclude . Patients must able perform technically acceptable pulmonary function test , maintain medication worksheet record study period , perform assessment require protocol . Patients must able inhale medication competent manner RESPIMAT inhaler meter dose inhaler ( MDI ) . Male female patient . Women childbearing potential* must ready able use highly effective method birth control per ICH M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly . A list contraception method meet criterion provide patient information . Women childbearing potential define : Any female experience menarche meet criterion `` woman childbearing potential '' describe . Women childbearing potential define : Women postmenopausal ( 12 month menses without alternative medical cause ) permanently sterilize ( e.g. , tubal occlusion , hysterectomy , bilateral oophorectomy bilateral salpingectomy ) . Exclusion criterion : Patients significant disease Chronic Obstructive Pulmonary Disease ( COPD ) ; significant disease define disease , opinion investigator , may ( ) put patient risk participation study , ( ii ) influence result study , ( iii ) cause concern regard patient 's ability participate study . Patients , opinion investigator , clinically relevant abnormal baseline haematology , blood chemistry , urinalysis ; patient Serum Glutamic Oxaloacetic Transaminase ( SGOT ) &gt; x 2 Upper Limit Normal ( ULN ) , Serum Glutamic Pyruvic Transaminase ( SGPT ) &gt; x 2 ULN , bilirubin &gt; x 2 ULN creatinine &gt; x 2 ULN exclude regardless clinical condition ( repeat laboratory evaluation conduct patient ) . Patients history asthma . For patient allergic rhinitis atopy , source documentation require verify patient asthma . If patient total blood eosinophil count ≥600/mm3 , source documentation require verify increase eosinophil count relate nonasthmatic condition . Patients follow condition : A diagnosis thyrotoxicosis ( due know class side effect profile ß2agonists ) . A diagnosis paroxysmal tachycardia ( &gt; 100 beat per minute ) ( due know class side effect profile ß2agonists ) A history myocardial infarction within 1 year screen visit ( Visit 1 ) . Unstable lifethreatening cardiac arrhythmia . Hospitalization heart failure within past year . Known active tuberculosis . A malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( patient treat basal cell carcinoma allow ) . A history lifethreatening pulmonary obstruction . A history cystic fibrosis . Clinically evident bronchiectasis . A history significant alcohol drug abuse . Patients undergone thoracotomy pulmonary resection ( patient history thoracotomy reason evaluate per exclusion criterion No . 1 ) . Patients treat oral patch βadrenergics . Patients treat oral corticosteroid medication unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . Patients regularly use daytime oxygen therapy one hour per day investigator 's opinion unable abstain use oxygen therapy clinic visit . Patients complete pulmonary rehabilitation program six week prior screen visit ( Visit 1 ) patient currently pulmonary rehabilitation program . Patients take investigational drug within one month six half life within wash period ( whichever great ) prior screen visit ( Visit 1 ) . Patients know hypersensitivity βadrenergics and/or anticholinergic drug , benzalkonium chloride ( BAC ) , EDTA component RESPIMAT inhalation solution . Women pregnant , nursing , plan become pregnant trial Women childbearing potential use two highly effective method birth control* . Female patient consider childbearing potential unless surgically sterilise hysterectomy bilateral tubal ligation , postmenopausal least two year . * per ICH M3 : highly effective method birth control define result low failure rate ( i.e. , less 1 % per year ) use consistently correctly . Patients previously allocate study currently participate another study . Patients unable comply pulmonary medication restriction prior allocation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>